Generic-drug giant Teva Pharmaceutical Industries Ltd. has agreed to acquire biopharmaceutical company CoGenesys Inc. for $400 million in cash, Teva announced Tuesday.
The deal, which is expected to close during the first half of 2008, is likely to stoke the debate about the role generic-drug makers should play in the emerging market for biological therapies.
CoGenesys Inc., a closely held spinoff of Human Genome Sciences Inc., would give Jerusalem-based Teva a foothold in the market for biologic therapies.
tag: Teva Pharmaceutical, CoGenesys,
No comments:
Post a Comment